From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Oxford BioDynamics – interims, funding outlook ‘as was the case at the previous period end’… but what about the already-raised net £8.5m since then?!

By Steve Moore | Tuesday 30 May 2023

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Describing itself as “a biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform”, Oxford BioDynamics (OBD) has announced results for its half-year ended 31st March 2023 emphasising “excellent progress across the business. There was sustained growth in orders of EpiSwitch CiRT tests, which has continued post-period end. Overwhelming demand for the PSE blood test after announcement of its high accuracy performance”. So what of a current share price response towards 13p, down approaching 22%?!
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Which PR genius wrote this?



H&T Group – now again a Buy

Time left: 06:31:55